Study Title: Phase Ib dose de-escalation study of the PI3K alpha/delta inhibitor, Copanlisib given in combination with the immunotherapeutic agents, Nivolumab and Rituximab in patients with relapsed/refractory indolent lymphoma. Big Ten Cancer Research Consortium BTCRC-LYM17-145
- Open to Accrual at:
- Closed to Accrual at:
- Learn more:
Study Contact: studies@hoosiercancer.org; (317) 921-2050.
Subscribe to the Big Ten CRC Newsletter
Twitter
Facebook
YouTube